The collaboration will span four years.

Agilent Technologies has entered into a strategic partnership with the National University of Singapore (NUS), through NUS Medicine, to establish a Center of Excellence in Cell Metabolism.

The collaboration aims to advance research in cardiovascular and metabolic diseases over the next four years.

Agilent's integrated metabolic and cellular phenotyping platforms, such as xCELLigence, Seahorse XF, and BioTek technologies enable efficient cell studies. This will facilitate the discovery of new therapeutic targets and cardio-liver-metabolic biomarkers to prevent CVDs.

According to GlobalData, global partnerships are expected to strengthen NUS' Project RESET, which aims to advance cardiovascular research in the country.

"By developing innovative, preventative healthcare strategies and enhancing local expertise in cardiovascular research, Singapore aims to reduce healthcare costs associated with CVDs. Furthermore, international collaborations will elevate Singapore's status as a hub for biomedical research, attracting investment, talent, and boosting the local economy over time," Shreya Jain, Medical Devices Analyst at GlobalData said.